• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Hemoglobin Levels and Mean Corpuscular Volume in Adults With Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对成年囊性纤维化患者血红蛋白水平和平均红细胞体积的影响。
Pediatr Pulmonol. 2025 Jan;60(1):e27428. doi: 10.1002/ppul.27428. Epub 2024 Nov 28.
2
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究（SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103）：两项随机、活性对照3期试验的结果
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
3
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（有或没有增效剂）。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
4
Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor.接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗的成年囊性纤维化相关糖尿病患者中，胰岛素剂量调整后的糖化血红蛋白降低。
J Clin Transl Endocrinol. 2025 Jul 2;41:100407. doi: 10.1016/j.jcte.2025.100407. eCollection 2025 Sep.
5
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
6
Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor.患有囊性纤维化相关糖尿病的青少年和成人在接受依列卡福-替扎卡福-依伐卡福治疗后，糖化血红蛋白水平降低。
J Cyst Fibros. 2025 Jul;24(4):755-758. doi: 10.1016/j.jcf.2025.03.007. Epub 2025 Mar 14.
7
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化：系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
8
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化儿童粪便弹性蛋白酶-1的影响。
Pediatr Pulmonol. 2025 Jun;60(6):e71156. doi: 10.1002/ppul.71156.
9
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis.依列卡福妥、替扎卡福妥和依伐卡福妥在成人囊性纤维化真实世界队列中的群体药代动力学
Clin Pharmacokinet. 2025 May 22. doi: 10.1007/s40262-025-01516-1.
10
Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR in the USA: a prospective, multicentre, open-label, single-arm trial.在美国对患有囊性纤维化和CFTR的个体进行的依列卡福托-替扎卡福托-依伐卡托治疗评估：一项前瞻性、多中心、开放标签、单臂试验。
Lancet Respir Med. 2024 Dec;12(12):947-957. doi: 10.1016/S2213-2600(24)00205-4. Epub 2024 Aug 26.

引用本文的文献

1
Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.接受CFTR调节剂治疗的囊性纤维化儿童的血红蛋白水平：一项单中心回顾性研究。
J Clin Med. 2025 Jul 9;14(14):4856. doi: 10.3390/jcm14144856.

本文引用的文献

1
Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.分析伊伐卡托/泰他卡托/艾美卡托起始治疗后囊性纤维化人群的铁状态。
Pediatr Pulmonol. 2024 Mar;59(3):669-678. doi: 10.1002/ppul.26805. Epub 2023 Dec 13.
2
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.依伐卡托/泰它卡托/艾氟卡托治疗囊性纤维化的临床疗效：一项临床试验。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Hepcidin and Anemia: A Tight Relationship.铁调素与贫血：紧密关系
Front Physiol. 2019 Oct 9;10:1294. doi: 10.3389/fphys.2019.01294. eCollection 2019.
5
Detection, evaluation, and management of iron-restricted erythropoiesis.铁缺乏性红细胞生成的检测、评估和管理。
Blood. 2010 Dec 2;116(23):4754-61. doi: 10.1182/blood-2010-05-286260. Epub 2010 Sep 8.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Hemoglobin Levels and Mean Corpuscular Volume in Adults With Cystic Fibrosis.

作者信息

James Amber, Li Z Galvin, Kwarteng Magdalene, List Rhonda, Albon Dana

机构信息

University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Department of Statistics, University of Virginia, Charlottesville, Virginia, USA.

出版信息

Pediatr Pulmonol. 2025 Jan;60(1):e27428. doi: 10.1002/ppul.27428. Epub 2024 Nov 28.

DOI:10.1002/ppul.27428
PMID:39607352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11748099/
Abstract
摘要